The place of thalidomide in the treatment of multiple myeloma
Thalidomide represents the first attempt in multiple myeloma (MM) patients to overcome resistance to chemotherapy through a biological agent. The exciting results reported in the first study by Singhal et al. in 1999 [1] led to several other studies which aimed to evaluate its efficacy in different...
Spremljeno u:
| Glavni autori: | , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2011-12-01
|
| Serija: | Oncology Reviews |
| Teme: | |
| Online pristup: | http://oncologyreviews.org/index.php/or/article/view/157 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|